玻璃体腔注射齐夫-阿柏西普的两年结局
该研究纳入接受至少6次玻璃体腔注射齐夫-阿柏西普(IVZ,1.25 mg/0.05 mL)且随访至少1年的连续性黄斑疾病患眼,评估两年视力与黄斑厚度结局。24个月时黄斑中心凹厚度显著下降133.0±153.0 µm,最佳矫正视力(BCVA)提高0.35±0.37(均P<0.001);1121次注射中报告1例一过性葡萄膜炎和1例视网膜中央动脉阻塞。作者认为IVZ在两年内治疗黄斑疾病似乎安全有效。
要点
- 24个月时黄斑中心凹厚度显著下降133.0±153.0 µm(P<0.001)。
- 24个月时BCVA提高0.35±0.37(P<0.001)。
- 1121次注射中报告1例一过性葡萄膜炎和1例视网膜中央动脉阻塞。
核心结论
- 作者认为,IVZ在两年内治疗黄斑疾病似乎安全有效。
研究设计与样本
- 纳入接受6次或以上0.05 mL IVZ(1.25 mg)注射且随访至少1年的连续性黄斑疾病受试者。
- 共纳入91名受试者的107只眼,随访间隔均值±标准差为1.48±0.44个月,采用治疗-延长或按需方案。
- 疾病分布包括新生血管性黄斑变性42只眼、糖尿病黄斑水肿32只眼和视网膜静脉阻塞继发黄斑水肿11只眼;50只眼为初治,57只眼既往接受过治疗。
主要发现
- 合并所有疾病类别,24个月随访时黄斑中心凹厚度显著下降133.0±153.0 µm(P<0.001)。
- 24个月随访时BCVA提高0.35±0.37(P<0.001)。
- 平均注射次数为第12个月8.5次、12至18个月间2.4次、18至24个月间1.7次。
- 1121次注射后报告1例一过性葡萄膜炎和1例视网膜中央动脉阻塞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To assess the two-year outcome of intravitreal ziv-aflibercept (IVZ) in eyes with macular diseases. METHODS: Consecutive subjects with various macular diseases that received six or more of 0.05 mL IVZ (1.25 mg) injections with at least 1 year follow-up were included. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution) and central macular thickness (CMT) on spectral domain optical coherence tomography. Paired comparison was done using Wilcoxon signed-rank test calculator. RESULTS: 107 eyes of 91 subjects received IVZ and were followed with mean±SD follow-up interval of 1.48±0.44 months following treat and extend or pro-re-nata protocol. The distribution included neovascular macular degeneration (42 eyes), diabetic macular oedema (32 eyes) and macular oedema secondary to retinal vein occlusion (11 eyes). Fifty eyes were naive, while 57 eyes were previously treated. Combining all disease categories, CMT decreased significantly by 133.0±153.0 µm at the 24-month follow-up (P<0.001) with BCVA gain of 0.35±0.37 at the 24-month follow-up (P<0.001) with mean number of injections of 8.5 at month 12, 2.4 between 12 and 18 month and 1.7 between 18 and 24 month. Ocular and systemic adverse effects included one episode of transient uveitis and one instance of central retinal artery occlusion after 1121 injections. CONCLUSIONS: IVZ appears safe and efficacious in the therapy of macular diseases through 2 years.
引用
- Mansour AM, Ashraf M, Charbaji A, et al. Two-year outcomes of intravitreal ziv-aflibercept. Br J Ophthalmol. 2018. PMID: 29317400. doi:10.1136/bjophthalmol-2017-311591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。